Financials in USD. Standardized financial statements.
A compact view of how NGM Biopharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $4.42M | $55.33M | $77.88M | $87.37M | $103.54M | $108.67M | $77.14M | $85.59M |
| Revenue Growth? | -92.0% | -29.0% | -10.9% | -15.6% | -4.7% | +40.9% | -9.9% | 0.0% |
| Cost of Revenue? | $2.22M | $5.98M | $7.90M | $163.97M | $129.25M | $0 | $0 | $0 |
| Gross Profit? | $2.20M | $49.35M | $69.98M | -$76.60M | -$25.71M | $108.67M | $77.14M | $85.59M |
| Gross Margin? | +49.7% | +89.2% | +89.9% | -87.7% | -24.8% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $148.74M | $221.58M | $198.58M | $191.20M | $152.88M | $112.98M | $94.57M | $93.95M |
| Operating Income? | -$146.55M | -$166.25M | -$120.69M | -$103.83M | -$49.34M | -$4.31M | -$17.43M | -$8.36M |
| EBITDA? | -$144.33M | -$154.92M | -$120.69M | -$103.83M | -$49.34M | $2.91M | -$10.98M | -$4.83M |
| Income Before Tax | -$142.38M | -$162.67M | -$120.33M | -$102.49M | -$42.80M | -$493,000 | -$15.22M | -$6.42M |
| Income Tax Expense | $0 | -$3.58M | -$6.51M | -$8.49M | -$14.30M | $0 | -$1.06M | $500,000 |
| Net Income? | -$142.38M | -$159.09M | -$113.83M | -$93.99M | -$28.50M | -$493,000 | -$14.16M | -$6.92M |
| EPS? | $-1.73 | $-1.99 | $-1.48 | $-1.37 | $-0.57 | $-0.01 | $-0.26 | $-0.13 |
| Diluted EPS? | $-1.73 | $-1.99 | $-1.48 | $-1.37 | $-0.57 | $-0.01 | $-0.26 | $-0.13 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality